EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models

Louis T Rodgers iD, John L Villano iD, Anika M S Hartz iD, Björn Bauer iD

Cancers · 24.07.2024 · 16 (15) · 2638

DOI: 10.3390/cancers16152638 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.07.2024. Verfasst von Louis T Rodgers und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) presents a significant public health challenge as the deadliest and most common malignant brain tumor in adults. Despite standard-of-care treatment, which includes surgery, radiation, and chemotherapy, mortality rates are high, underscoring the critical need for advancing GBM therapy. Over the past two decades, numerous clinical trials have been performed, yet only a small fraction demonstrated a benefit, raising concerns about the predictability of current preclinical models. Traditionally, preclinical studies utilize treatment-naïve tumors, failing to model the clinical scenario where patients undergo standard-of-care treatment prior to recurrence. Recurrent GBM generally exhibits distinct molecular alterations influenced by treatment selection pressures. In this review, we discuss the impact of treatment—surgery, radiation, and chemotherapy—on GBM. We also provide a summary of treatments used in preclinical models, advocating for their integration to enhance the translation of novel strategies to improve therapeutic outcomes in GBM.

Schlagwörter

Stichwörter der Autor:innen

glioblastomapreclinical modelsradiation therapyrecurrent tumorresectionreverse translationstandard of caretemozolomide

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA.
  • Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • Department of Medicine, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • Department of Neurology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • Department of Neurosurgery, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.

ORCID-Profile: Louis T Rodgers, John L Villano, Anika M S Hartz, Björn Bauer

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institute of Neurological Disorders and Stroke of the National Institutes of Health
  • National Center for Advancing Translational Sciences of the National Institutes of Health
  • Northern Kentucky/Greater Cincinnati UK Alumni Club Fellowship (LTR)

Zitieren

APA

Rodgers, L. T., Villano, J. L., Hartz, A. M. S., & Bauer, B. (2024). Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models. Cancers, 16(15), 2638. https://doi.org/10.3390/cancers16152638

Vancouver

Rodgers LT, Villano JL, Hartz AMS, Bauer B. Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models. Cancers. 2024;16(15):2638. doi:10.3390/cancers16152638

BibTeX
@article{Rodgers2024,
  author = {Rodgers, Louis T and Villano, John L and Hartz, Anika M S and Bauer, Björn},
  title = {Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {15},
  pages = {2638},
  doi = {10.3390/cancers16152638}
}
Kostenlos starten →